Metsera Stock (NASDAQ:MTSR)
Previous Close
$34.58
52W Range
$12.30 - $37.99
50D Avg
$24.24
200D Avg
$26.03
Market Cap
$3.09B
Avg Vol (3M)
$1.06M
Beta
0.40
Div Yield
-
MTSR Company Profile
Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity. The company was incorporated in 2022 and is headquartered in New York, New York.